Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
By S. Castaigne, C. Pautas, C. Terré, E. Raffoux, D. Bordessoule, J. Bastie, O. Legrand, X. Thomas, P. Turlure, O. Reman and 12 more. The Lancet, 2012
904 citations recorded by the source corpus.
Subfields: Hematology
View Paper: https://www.semanticscholar.org/paper/2f4b2379fff2a66c3ccfd50f32e0a28ffcca90fb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
Citations in the corpus
- Antibody drug conjugate: the “biological missile” for targeted cancer therapy (2022, methodology): “Based on the overall positive outcomes achieved in above three investigator-led clinical trials, thus the Mylotarg was re-approved by the FDA in 2017.(149,151,152) Recently, a new indication of gemtuzumab ozogamicin was approved by the FDA for the treatment of newly-diagnosed CD33-positive AML to in”
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, background): “found survival benefit with GO, largely attributable to fewer relapses in patients with favorable- or intermediate-risk cytogenetics.(150,151) An individual patient data meta-analysis of these four studies and a fifth published in abstract form reinforced these conclusions.”